摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-N-[2′-(pyridin-2″-yl)acetamido]morphinan-6-one

中文名称
——
中文别名
——
英文名称
17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-N-[2′-(pyridin-2″-yl)acetamido]morphinan-6-one
英文别名
N-[(4R,4aS,7aR,12bR)-3-(cyclopropylmethyl)-9-hydroxy-7-oxo-2,4,5,6,7a,13-hexahydro-1H-4,12-methanobenzofuro[3,2-e]isoquinolin-4a-yl]-2-pyridin-2-ylacetamide
17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-N-[2′-(pyridin-2″-yl)acetamido]morphinan-6-one化学式
CAS
——
化学式
C27H29N3O4
mdl
——
分子量
459.545
InChiKey
KJFHGLXEDWDISS-NVSKSXHLSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.5
  • 重原子数:
    34
  • 可旋转键数:
    5
  • 环数:
    7.0
  • sp3杂化的碳原子比例:
    0.52
  • 拓扑面积:
    91.8
  • 氢给体数:
    2
  • 氢受体数:
    6

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为产物:
    描述:
    蒂巴因盐酸sodium periodate 、 lithium aluminium tetrahydride 、 palladium 10% on activated carbon 、 氢气sodium acetate吡啶盐酸盐三溴化硼1-羟基苯并三唑溶剂黄146盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺三乙胺 作用下, 以 四氢呋喃甲醇乙醇二氯甲烷乙酸乙酯N,N-二甲基甲酰胺 为溶剂, 20.0 ℃ 、413.7 kPa 条件下, 反应 9.25h, 生成 17-cyclopropylmethyl-4,5α-epoxy-3-hydroxy-14β-N-[2′-(pyridin-2″-yl)acetamido]morphinan-6-one
    参考文献:
    名称:
    Design, Synthesis, and Biological Evaluation of 14-Heteroaromatic-Substituted Naltrexone Derivatives: Pharmacological Profile Switch from Mu Opioid Receptor Selectivity to Mu/Kappa Opioid Receptor Dual Selectivity
    摘要:
    On the basis of a mu opioid receptor (MOR) homology model and the isosterism concept, three generations of 14-heteroaromatically substituted naltrexone derivatives were designed, synthesized, and evaluated as potential MOR-selective ligands. The first-generation ligands appeared to be MOR-selective, whereas the second and the third generation ones showed MOR/kappa opioid receptor (KOR) dual selectivity. Docking of ligands 2 (MOR selective) and 10 (MOR/KOR dual selective) to the three opioid receptor crystal structures revealed a nonconserved-residue-facilitated hydrogen-bonding network that could be responsible for their distinctive selectivity profiles. The MOR/KOR dual-selective ligand 10 showed no agonism and acted as a potent antagonist in the tail-flick assay. It also produced less severe opioid withdrawal symptoms than naloxone in morphine-dependent mice. In conclusion, ligand 10 may serve as a novel lead compound to develop MOR/KOR dual-selective ligands, which might possess unique therapeutic value for opioid addiction treatment.
    DOI:
    10.1021/jm4012214
点击查看最新优质反应信息

文献信息

  • Design, Synthesis, and Biological Evaluation of 14-Heteroaromatic-Substituted Naltrexone Derivatives: Pharmacological Profile Switch from Mu Opioid Receptor Selectivity to Mu/Kappa Opioid Receptor Dual Selectivity
    作者:Yunyun Yuan、Saheem A. Zaidi、Orgil Elbegdorj、Lindsey C. K. Aschenbach、Guo Li、David L. Stevens、Krista L. Scoggins、William L. Dewey、Dana E. Selley、Yan Zhang
    DOI:10.1021/jm4012214
    日期:2013.11.27
    On the basis of a mu opioid receptor (MOR) homology model and the isosterism concept, three generations of 14-heteroaromatically substituted naltrexone derivatives were designed, synthesized, and evaluated as potential MOR-selective ligands. The first-generation ligands appeared to be MOR-selective, whereas the second and the third generation ones showed MOR/kappa opioid receptor (KOR) dual selectivity. Docking of ligands 2 (MOR selective) and 10 (MOR/KOR dual selective) to the three opioid receptor crystal structures revealed a nonconserved-residue-facilitated hydrogen-bonding network that could be responsible for their distinctive selectivity profiles. The MOR/KOR dual-selective ligand 10 showed no agonism and acted as a potent antagonist in the tail-flick assay. It also produced less severe opioid withdrawal symptoms than naloxone in morphine-dependent mice. In conclusion, ligand 10 may serve as a novel lead compound to develop MOR/KOR dual-selective ligands, which might possess unique therapeutic value for opioid addiction treatment.
查看更多